Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia

Leukemia

Volumn 19, Issue 11, 2005, Pages 1941-1947

  Meng, Y S ^a   Khoury, H ^a   Dick, J E ^a   Minden, M D ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

AML; Differentiation; Drug resistance; Expression; LYL1

Indexed keywords

CD34 ANTIGEN; COMPLEMENTARY DNA; CYTARABINE; HELIX LOOP HELIX PROTEIN; HEMIN; TRANSCRIPTION FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CARCINOGENICITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; DRUG RESISTANCE; ELECTROPORATION; ERYTHROID CELL; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH RATE; HEMATOPOIESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; MALE; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RETROVIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 27644497232     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403836     Document Type: Article

References (16)

1. Cleary ML, Mellentin JD, Spies J, Smith SD. Chromosomal translocation involving the beta T cell receptor gene in acute leukemia. J Exp Med 1988; 167: 682-687.
2. Mellentin JD, Smith SD, Cleary ML. lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 1989; 58: 77-83.
3. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75-87.
4. Ferrier R, Nougarede R, Doucet S, Kahn-Perles B, Imbert J, Mathieu-Mahul D. Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105. Oncogene 1999; 18: 995-1005.
5. Bruckner R, Jentsch-Ullrich K, Franke A, Wieacker P, Stumm M. A novel translocation (17;19)(p13;p13) in a patient with acute myelomonocytic leukemia. Cancer Genet Cytogenet 2000; 119: 77-79.
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
7. McCulloch EA, Minden MD, Curtis JE. The influence of growth regulation on treatment strategy for acute myeloblastic leukaemia. Cancer Surv 1990; 9: 169-198.
8. Han Y, San Marina S, Liu J, Minden MD. Transcriptional activation of c-myc proto-oncogene by WT1 protein. Oncogene 2004; 23: 6933-6941.
9. Asnafi V, Beldjord K, Libura M, Villarese P, Millien C, Ballerini P et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood 2004; 104: 4173-4180.
10. Miyamoto A, Cui X, Naumovski L, Cleary ML. Helix-loop-helix proteins LYL1 and E2a form heterodimeric complexes with distinctive DNA-binding properties in hematolymphoid cells. Mol Cell Biol 1996; 16: 2394-2401.
11. Keating A, Horsfall W, Hawley RG, Toneguzzo F. Effect of different promoters on expression of genes introduced into hematopoietic and marrow stromal cells by electroporation. Exp Hematol 1990; 18: 99-102.
12. Hu ZB, Minden MD, McCulloch EA, Stahl J. Regulation of drug sensitivity by ribosomal protein S3a. Blood 2000; 95: 1047-1055.
13. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
14. Visvader J, Begley CG, Adams JM. Differential expression of the LYL, SCL and E2A helix-loop-helix genes within the hemopoietic system. Oncogene 1991; 6: 187-194.
15. Ballerini P, Blaise A, Busson-Le Coniat M, Su XY, Zucman-Rossi J, Adam M et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood 2002; 100: 991-997.
16. Bernard M, Delabesse E, Novault S, Hermine O, Macintyre EA. Antiapoptotic effect of ectopic TAL1/SCL expression in a human leukemic T-cell line. Cancer Res 1998; 58: 2680-2687.